The purpose of the Administrative Core is to provide support for the integrated Program on Lung Cancer Targeted Therapies, whose ultimate goal is to translate genomic events into the therapy of patients with nonsmall cell lung cancer (NSCLC) by discovery, testing, and validating kinase inhibitors as targeted therapies for genomically selected NSCLC . Specifically, the Core Director and Co-Director will provide guidance and oversight to the Projects and shared research Cores and will lead the evaluation of research progress including consultation with an Internal Advisory Committee and an External Advisory Board. The Administrative Core of this Program Project application is to coordinate these interrelated complementary research projects to maximize their scientific synergy and to share the findings with the scientific community. The Core Directors will co-ordinate staff assistance to projects including administrative support to facilitate scientific progress including meeting arrangements, editorial services for manuscript preparation, and web development services for internal and external communications.
The specific aims of the Administrative Core are summarized below.
Specific Aim 1 : Monitor projects and shared resource cores and to evaluate overall research progress.
Specific Aim 2 : Foster collaboration and communication among the projects and shared resource cores.
Specific Aim 3; Provide fiscal oversight and support for the program.
Specific Aim 4 : Promote the clinical translation of diagnostic and therapeutic discoveries from the program.

Public Health Relevance

To accomplish a complex, multi-investigator research effort such as the Program in Lung Cancer Targeted Therapies, which could achieve a real impact on lung cancer treatment, requires significant co-ordination among Projects, Cores, and investigators within the Program. The Administrative Core will accomplish this necessary co-ordination and oversight.

National Institute of Health (NIH)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Wang, J; Mikse, O; Liao, R G et al. (2015) Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 34:2167-77
Berger, A H; Imielinski, M; Duke, F et al. (2014) Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33:4418-23
Nakayama, Sohei; Sng, Natasha; Carretero, Julian et al. (2014) ?-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res 74:5891-902
Chen, Zhao; Akbay, Esra; Mikse, Oliver et al. (2014) Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 20:1204-11
Herter-Sprie, Grit S; Korideck, Houari; Christensen, Camilla L et al. (2014) Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun 5:5870
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34
Christensen, Camilla L; Kwiatkowski, Nicholas; Abraham, Brian J et al. (2014) Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26:909-22
Canning, Peter; Tan, Li; Chu, Kiki et al. (2014) Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 426:2457-70
Chen, Zhao; Fillmore, Christine M; Hammerman, Peter S et al. (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535-46
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90

Showing the most recent 10 out of 24 publications